How Hospitals Make Money on 340B: Drug Margins and the Verification Dispute

Hospitals make money on 340B by buying outpatient drugs at discounted prices and collecting reimbursement that can exceed what they paid. The hospital gets the purchase discount. The patient can still pay the full non-340B price. For someone in pharmacy, billing or finance, the important story is in the gap between the purchase, the prescription and the claim.

How Do Hospitals Make Money on 340B?

The manufacturer supplies the discount, while Medicare and other insurers pay under their own reimbursement rules. What the hospital pays and what it collects are separate decisions.

The Health Resources and Services Administration administers the program, which is intended to help qualifying providers reach more patients and offer more services. In its 2025 overview, the Government Accountability Office cites the agency’s estimated purchase discounts of 20 to 50 percent.

The same transaction also has eligibility restrictions. Hospital 340B diversion and duplicate discounts concern who receives the discounted drugs and whether a manufacturer pays a Medicaid rebate on a drug it has already discounted.

Hospital Eligibility Opens the Purchase Account

Six hospital categories can participate: disproportionate-share hospitals, children’s hospitals, free-standing cancer hospitals, rural referral centers, sole community hospitals and critical access hospitals. Their requirements differ. The program also covers qualifying federal grantees, including health centers.

For disproportionate-share hospitals, the Health Resources and Services Administration’s eligibility requirements include an adjustment percentage greater than 11.75% on the most recently filed hospital cost report. A number the hospital reports about itself opens access to discounted drug purchases.

The hospital must also be government-owned or operated, a nonprofit corporation with formally granted governmental powers, or a private nonprofit with a state or local government contract to provide health care to low-income people outside Medicare and Medicaid. For-profit hospitals are excluded. The agency registers eligible hospitals during quarterly windows and requires annual recertification.

340B Discounted Purchases Versus Savings

Discounted purchases measure what providers spend. Savings measure the price reduction. In its purchase report for 2025, the Health Resources and Services Administration reported $79,235,079,126 in purchases by disproportionate-share hospitals out of $100,010,973,317 across all provider categories. Reimbursement and dispensing costs determine how much hospitals keep.

The agency identifies outpatient oncology drugs, biologics and other infusion therapies as the program’s fastest-growing purchase segment. Expensive drugs make the difference between acquisition cost and reimbursement especially important to hospital finances.

The Government Accountability Office’s 2015 Medicare Part B drug study found average drug spending per beneficiary of $144 at 340B disproportionate-share hospitals in 2012, compared with approximately $60 at nonparticipating hospitals. The hospital characteristics and patient health measures the study examined did not appear to explain the difference. It identified an incentive to prescribe more drugs or more expensive drugs, with larger copayments for patients when that happens.

The Hospital’s Discount Can Leave the Patient’s Price Untouched

The program has no general requirement that hospitals pass their purchase discount directly to patients. Eligible patients can have insurance or pay for their own care, and the statute does not direct how providers must spend the savings or resulting revenue.

In a small, selected sample described in the Inspector General’s 2014 contract-pharmacy report, eight of thirty providers reported offering uninsured patients no 340B price at any of their contract pharmacies. Seven of those eight were disproportionate-share hospitals. Those patients paid the full non-340B price. Some administrators identified prescriptions as eligible only after patients had already paid.

Contract Pharmacy Patient Eligibility Depends on Hospital Records

A contract pharmacy fills prescriptions on the hospital’s behalf, but the hospital remains responsible for the arrangement’s compliance. Under the patient guidance described by the Government Accountability Office, the connection rests on healthcare records and the hospital’s responsibility for care. The prescription’s eligibility has to follow that connection through the dispensing system.

The Inspector General described two inventory models. Under one, the pharmacy keeps the hospital’s discounted drugs in stock separately from its own drugs. Under replenishment, the pharmacy dispenses its own stock first. The hospital later buys replacement quantities at the discounted price for delivery to the pharmacy. Administrators track the dispensed quantities and match prescriptions against hospital data.

That is where hospital records become money. The report describes patient and prescriber lists, eligible-site lists, clinical information and encounter records feeding those decisions. Different providers used different matching methods. An ineligible site’s prescriptions entering the discounted account can be a hospital 340B diversion issue, even when the hospital itself meets the enrollment requirements.

Hospitals register associated child sites, including off-site outpatient clinics, through the 340B Office of Pharmacy Affairs Information System. Those sites must meet the program’s requirements too.

The pharmacy also takes a share of the economics. In its 2018 review of contract-pharmacy agreements, the Government Accountability Office found that most agreements it examined paid the pharmacy a flat fee for each eligible prescription. Some also paid a percentage of prescription revenue. The difference between the insurer’s payment and the drug invoice therefore has more than one destination.

Duplicate Medicaid discounts involve a separate match. A manufacturer supplies a 340B discount and also pays a Medicaid rebate for the same drug. States need to identify discounted drugs before requesting rebates, including drugs paid through Medicaid managed-care plans.

Carve-in means using 340B drugs for Medicaid patients. Carve-out means using drugs purchased outside 340B. The Medicaid Exclusion File identifies providers using 340B drugs for Medicaid fee-for-service patients. It does not cover managed care, where the same matching problem needs a different control.

A Closed 340B Audit Can Leave the Correction Unverified

The Health Resources and Services Administration’s process for 340B audit closure does not ensure that providers have fully corrected the violations, GAO reported in October 2025. Under that process, providers submit corrective-action plans and then attest that they have implemented them and completed any necessary manufacturer repayments. Most do not have to supply documentation proving implementation before the audit closes.

A hospital’s corrective-action response and its subsequent dispensing activity can tell different stories. For an employee who sees the same ineligible prescriptions continue to enter the system, the closure letter and the later transactions belong in the same conversation.

The same review found that hospital 340B duplicate-discount audits assessed Medicaid fee-for-service transactions without fully assessing managed-care transactions. That leaves a gap between the audit’s scope and the hospital’s drug business.

Hospital eligibility has its own verification problem. On retroactive government contracts, the Government Accountability Office said the agency still needed to demonstrate that it had stopped accepting documentation created to cover earlier periods and had addressed hospitals lacking contracts in effect before their audit periods. The contract’s effective date matters because it supports the hospital’s access to the discount.

We connect an HRSA hospital repayment finding with what happened next: whether the hospital knew the problem continued and kept billing the government. That connection matters to a hospital False Claims Act case, and we work through it with you.

Medicare Reimbursement Changes the Hospital’s Margin

Medicare’s 340B payment dispute concerns how much the insurer pays after the hospital has bought the drug at a discount. A reduction in reimbursement narrows the hospital’s margin.

In 2018, Medicare cut payment for affected drugs from average sales price plus 6% to average sales price minus 22.5%. The Supreme Court struck down the different rates in 2022 because the government had not surveyed hospitals’ acquisition costs before setting them. Medicare restored its ordinary drug-payment formula and paid hospitals $9 billion in one-time remedy payments in 2024.

The remedy also affected payments for services other than drugs. The earlier drug cuts had financed higher non-drug payments across hospitals. Under the repayment policy described by Medicare, affected non-drug outpatient payment rates fell by 0.5% annually starting in 2026 to recover about $7.8 billion.

The July 2026 proposed payment rule returned with an acquisition-cost survey. For 2027, Medicare proposed paying average sales price minus 33.4% for 340B drugs, with an offsetting increase in non-drug payments. It separately proposed accelerating the earlier non-drug repayment reduction to 3%.

The government returned with the survey the Court said was missing and proposed a drug payment rate below the one hospitals had defeated. Those later rates are proposals, separate from the repayment reduction already in effect.

The Rebate Pilot Changes When the Hospital Gets Its Discount

The revised hospital 340B rebate pilot would move the discount from the purchase price to a payment after dispensing. The hospital would order selected drugs at wholesale acquisition cost, submit claim data and receive the difference between that price and the 340B ceiling price applicable on the dispensing date.

The Health Resources and Services Administration’s August 3, 2026 revised notice followed the withdrawal of the earlier pilot and a court’s February 2026 order striking down its notices and manufacturer approvals. The revised notice sets a planned January 1, 2027 start for approved manufacturer plans covering drugs on Medicare’s selected-drug lists for 2026 and 2027.

The notice gives providers at least 45 calendar days after dispensing to submit data and requires payment or a documented denial within ten calendar days after a complete submission.

The notice bars rebate denials based on concerns about patient eligibility, diversion or Medicaid duplicate discounts. Manufacturers must bring those concerns to HRSA or the program’s audit and dispute processes.

Provider commenters objected to the cash-flow burden, additional staff and system changes. The agency expects timely rebates to arrive, in most cases, before wholesaler invoices fall due. The pilot’s planned evaluation includes payment timeliness, denials and administrative burden. For hospital finance, when the discount arrives can matter alongside how much it is worth.

California’s Acquisition-Cost Rule Changed What Hospitals Could Bill

California’s Medi-Cal acquisition-cost requirement tied payment for 340B drugs to what hospitals actually paid for them. The billing allegation in the following settlements concerns the price submitted for reimbursement after that requirement applied.

MemorialCare Health System allegedly continued billing higher usual and customary costs after a court lifted a temporary restriction on the California requirement. The Justice Department’s November 2, 2020 announcement put its settlement at $31,532,679, or 1.5 times the alleged overbilling. The alleged excess charges ran from December 2016 through October 2019. An internal audit led to a voluntary disclosure that October.

Pomona Valley Hospital Medical Center later settled allegations involving the same pricing change. Its alleged overbilling ran from December 2016 through September 2021. It disclosed the problem in 2021 and 2023, and the Justice Department announced the settlement in February 2024. Pomona Valley agreed to pay $873,730 to the United States and $1,225,954 to California.

The recurring decision was whether to change billing when the payment requirement changed. The government’s allegations connect the lower actual drug cost to claims seeking the higher amount. The alleged excess charges fell on federal and state taxpayers.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

Behind the 340B Margin

If you know why an ineligible prescription reached the discounted account or why billing continued after a pricing problem surfaced, speak with our whistleblower experts about those decisions. We connect what you saw in pharmacy, compliance or finance to the claims it produced and bring in whistleblower lawyers who know hospital drug-pricing cases. We stay beside you from that first assessment through the case’s resolution.